Overview

To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Sandoz
Treatments:
Bupropion